[ad_1]
Al-Wiamam-Riyadh-Mohammed Al-Suwaihri
The Ministry of Health today revealed the truth about what is going on about a drug to treat cancer."A reference to recent media and networks has shown that Vitrakvi is the commercial name of Larotrectinib," the ministry said in a statement.
And that this drug does not completely cure the cancer or the original cure, as mentioned, but aims to control the growth and spread as long as possible and does not replace the surgical treatment, chemotherapy and radiotherapy.
The New England Journal of Medicine published the study on larotrectinib, which was in its first and second stages. It involved 55 patients with cancer who had the TRK genetic mutation. The response rate was 13% and the partial response rate was 62%. Was long in all patients where the development of the disease in some participants in the study and continued to meet 39% of patients after the first year of treatment and some patients have undergone surgery after the drug.
This new treatment has recently been approved by the US Food and Drug Administration to treat specific cancer cases with a specific type of rare genetic mutations (TRK gene). This rare mutation is present in certain tumors such as the salivary gland, the thyroid, the lung and the connective tissue. Contains a genetic mutation and can not tolerate surgery, as well as cases containing a genetic mutation that are not an appropriate alternative to treatment, as well as cases that occur after the prescribed treatment.
The announcement by the Food and Drug Administration (FDA) of the world's first drug that can treat cancer from its source to adults and children has sparked controversy in the oncologist's scientific community. advocates of the new treatment and those who underestimate its scientific value.
The Arab and international media announced the announcement by the body of the drug Vitrakvi, which, according to Scott Gottlieb, the commissioner, uses to fight against genetic mutations of cancerous tumors, regardless of the type or place of the disease.
"Thank goodness, it's a new success and a new discovery in the treatment of cancer," Dr. Fahd al-Khudairy, a professor in the department of oncology, wrote on his Twitter page. . This drug targets the genetic origin of cancer and treats the origin of the tumor and mutant genes before the tumor spreads. (And the first drug with these specifications, and will change the methods of treatment to 100%, God willing.
The response to the drug was encouraging, with 75% of patients receiving the drug, while 73% of the responses took six months to respond to the drug. The least.
On the other hand, the cancer tumor specialists have reduced the size of the new scientific discovery, pointing out that it was based on a media sensation "greater than its real value".
"Lartigectinib, a commercially known drug called Vitracopy, is a new, recently approved FDA (Food and Drug Administration) treatment to treat specific cancer cases with a specific type of genetic mutagen (TRK gene)," he said. Dr. Ahmed Al Shammari, consultant in oncology. Healing cancer from its roots (healing), but aims to control its growth and spread for as long as possible. "
Al-Shammari said that the study's results, according to the published NEGM Medical, reported that 55 patients had been tested with a 75-80% response rate and that 55% of the patients did not have the same symptoms. had not developed or developed the disease after one year of treatment. Photos of the study with his twitter.
Dr. Mohammed Nasif, Associate Professor of Oncology at King Abdul Aziz University of Jeddah, endorsed the limited perspective on the value of the new treatment, explaining that it deals with specific tumors that represent a small percentage and target some cancer cells and not all.
On the other hand, the announcement of a new drug for the treatment of cancer is finally a great hope for many patients with these serious diseases, as well as for their families and loved ones, who have reprimanded the label of "cancer treatment" and expressed their joy at the discovery of new scientific data. Helping to relieve the pain and suffering of patients.
The United States Food and Drug Administration (FDA) announced yesterday that it has approved the world's first drug to treat cancer, from its source in the beginning, to the adult and to the child .
"The approval of the authorization and the introduction of this drug is an important step in the treatment of cancer, since it treats it from its source and treats the gene base of cancerous tumors independently from the location of their origin in the human body, "said Commissioner Scott Gottlieb.
By adding that the new drug will help cancer patients to get proper treatment and will help treat people with tumors of different cancers but with common genetic mutations.
"Traditionally, cancer was treated on the basis of cancerous growth, but now the treatment will be anywhere in the body because you are treating the original gene that caused the tumor," he said. said Dr. David Hayman, president of the Center for Early Drug Development, based in New York.
The drug has actually been tested on humans and a child was cured a few months after taking it: the drug will be administered on two bodies, the first in the form of tablets or capsules and the other in the form of a drug for children.
Dr. Ahmed Mahmoud, a researcher in the field of immunotherapy and cancer viruses at Harvard University, said the US statement contained many inaccuracies.
Mahmoud explained that the treatment is excellent, but that some tumors result from a particular mutation that leads to proteins different from natural ones. He explained: the treatment will not be administered and will not work with tumors that do not contain this mutation.
He pointed out that the diseases treated by this treatment are not common, but can be found in cancers of the salivary gland, thyroid gland, lung and some other tumors.
He pointed out that the proportion of tumors with this genetic defect is simple. Noting that Hanat certain conditions for the use of treatment in addition to the presence of mutation.
Source link
